Employees: 42
Size Egetis Therapeutics (EGTX.ST) is a Sweden Health Care company (Pharmaceuticals: Major) with a market value of $509M, the 172nd largest of 220 Sweden companies the cockpit tracks. Shares closed at SEK 11.14 on 18 Nov 2026.
Performance Over six months the shares gained 76.0%, against -20.4% for the median peer and +2.8% for the Sweden market (cap-weighted) — 3rd highest of 19 in its peer set.
Growth Revenue grew 26.7% over the last twelve months (peer median +7.6%); the operating margin is -644.9% (peer median 11.4%).
Valuation It trades at 15.1× forward earnings against a peer median of 14.3× (3rd cheapest of 5).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | SEK 70.2M | SEK 62.4M | SEK 46.1M | SEK 57.6M | SEK 22.6M |
| Revenue growth | — | +35% | -20% | +155% | — |
| Gross profit | SEK 19.5M | SEK 12.4M | SEK 34.5M | -SEK 127M | -SEK 60.7M |
| EBITDA | n/a | -SEK 343M | -SEK 324M | -SEK 317M | -SEK 194M |
| Net income | -SEK 470M | -SEK 342M | -SEK 344M | -SEK 327M | -SEK 194M |
| Free cash flow | -SEK 353M | -SEK 268M | -SEK 228M | -SEK 278M | -SEK 174M |
| Capital expenditure | SEK 1.00M | SEK 1.50M | SEK 0 | SEK 0 | SEK 0 |
| Total debt | SEK 73.9M | SEK 85.0M | SEK 117M | SEK 113M | SEK 2.70M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | EGTX.ST | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +21.5% | -7.0% | 2nd highest of 20 |
| 6-month return | +76.0% | -20.4% | 3rd highest of 19 |
| Distance from 52-week high | -0.5% | -40.7% | highest of 20 |
| Revenue growth (TTM) | +26.7% | +7.6% | 2nd highest of 19 |
| Operating margin | -644.9% | 11.4% | lowest of 19 |
| Forward P/E | 15.1× | 14.3× | 3rd cheapest of 5 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Egetis Therapeutics EGTX.ST | Sweden | $509M | +76% | +27% | -645% | 15.1× | n/a | n/a |
| Xizang Weixinkang Pharmaceutical 603676.SS | China | $513M | -22% | -8% | 16% | n/a | -6.1% | +9.6% |
| Indaptus Therapeutics INDP | United States | $505M | +147% | n/a | n/a | n/a | n/a | n/a |
| Gujarat Themis Biosyn GUJTHEM.NS | India | $505M | +2% | +18% | 39% | n/a | n/a | n/a |
| Shanghai Xiao Fang Pharmaceutical 603207.SS | China | $503M | -17% | +10% | 39% | n/a | -5.4% | +7.6% |
| Beijing Science Sun Pharmaceutical 300485.SZ | China | $517M | -29% | -11% | -8% | n/a | n/a | n/a |
| Gyre Therapeutics GYRE | United States | $500M | -28% | +14% | -18% | n/a | n/a | n/a |
| Henan Taloph Pharmaceutical Stock 600222.SS | China | $497M | -21% | -5% | 7% | n/a | 16.7% | +4.4% |
| Alpha Teknova TKNO | United States | $496M | +113% | +15% | -32% | n/a | n/a | n/a |
| Jiangsu Lianhuan Pharmaceutical 600513.SS | China | $496M | -41% | +14% | 0% | n/a | n/a | n/a |
| Daewoong 003090.KS | South Korea | $495M | -28% | +6% | 11% | 4.1× | n/a | n/a |
| Aarti Drugs AARTIDRUGS.NS | India | $494M | +34% | +15% | 11% | 21.3× | 22.1% | +3.5% |
| Shandong Wohua Pharmaceutical 002107.SZ | China | $493M | -20% | -4% | 18% | n/a | 5.9% | -4.1% |
| Tong Ren Tang Technologies 1666.HK | Hong Kong | $491M | -19% | -14% | 12% | 7.3× | -17.2% | +6.3% |
| Evonile Pharma EVONILE.NS | India | $529M | n/a | -5% | 12% | n/a | 49.3% | -1.5% |
| Supriya Lifescience SUPRIYA.NS | India | $529M | -15% | +23% | 26% | 36.2× | 28.2% | +15.8% |
| Jinling Pharmaceutical 000919.SZ | China | $529M | -15% | -8% | 1% | n/a | 2.4% | +5.0% |
| Electra Therapeutics ETRA | United States | $530M | n/a | n/a | n/a | n/a | n/a | n/a |
| Newland Pharmaceutical 301277.SZ | China | $488M | -22% | +9% | 11% | n/a | 8.9% | +9.1% |
| Nanjing Hicin Pharmaceutical 300584.SZ | China | $487M | -29% | +32% | 17% | n/a | 3.3% | -1.1% |
| Chimin Health Management 603222.SS | China | $533M | -31% | +1% | -28% | n/a | n/a | n/a |